Maxim Group Upgrades Keryx Biopharmaceuticals (KERX) to Buy

November 9, 2016 11:42 AM EST
Get Alerts KERX Hot Sheet
Price: $5.96 --0%

Rating Summary:
    8 Buy, 7 Hold, 2 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 2 | Down: 5 | New: 1
Trade KERX Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Maxim Group upgraded Keryx Biopharmaceuticals (NASDAQ: KERX) from Hold to Buy.

For an analyst ratings summary and ratings history on Keryx Biopharmaceuticals click here. For more ratings news on Keryx Biopharmaceuticals click here.

Shares of Keryx Biopharmaceuticals closed at $4.79 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Upgrades

Related Entities

Maxim Group

Add Your Comment